Qiurong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Qiurong Wang has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Jun Ren
Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, China
8 shared publications Xihui Xu
Center for Cardiovascular Research and Alternative Medicine, University of Wyoming College of Health Sciences, Laramie, WY 82071, USA
4 shared publications- Zaixing Huang
School of Chemical Engineering and Technology China University of Mining and Technology Xuzhou China
4 shared publications Hongguang Guo
3 shared publicationsMichael A. Urynowicz
3 shared publicationsSong Jin
3 shared publications
Latest Publications
- Open Access
- 22 August 2022
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 7 (8) , 779-796
Parkin Insufficiency Accentuates High-Fat Diet–Induced Cardiac Remodeling and Contractile Dysfunction Through VDAC1-Mediated Mitochondrial Ca2+ Overload
- 22 August 2022
- Published by Elsevier in JACC: Basic To Translational Science
- Vol. 7 (8) , 779-796
Open AccessParkin Insufficiency Accentuates High-Fat Diet–Induced Cardiac Remodeling and Contractile Dysfunction Through VDAC1-Mediated Mitochondrial Ca2+ Overload
- 1 June 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1865 (6) , 1627-1641
Mitochondrial ALDH2 protects against lipopolysaccharide-induced myocardial contractile dysfunction by suppression of ER stress and autophagy
- 1 June 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1865 (6) , 1627-1641
Mitochondrial ALDH2 protects against lipopolysaccharide-induced myocardial contractile dysfunction by suppression of ER stress and autophagy
- 11 March 2019
- Published by Taylor & Francis in Journal of the American College of Nutrition
- Vol. 38 (7) , 577-585
Safety and Efficacy of N-SORB®, a Proprietary KD120 MEC Metabolically Activated Enzyme Formulation: A Randomized, Double-Blind, Placebo-Controlled Study
Background: Enzymes are crucial for all aspects of metabolic function. Digestive enzymes from natural sources have been credited with beneficial effects in the digestion and absorption of food. N-SORB is a novel KD120 multienzyme complex (MEC) of metabolically activated enzymes composed of proteases, amylases, lipases, alpha-galactosidase, and glucoamylase from natural sources. These enzymes are encapsulated in a SK713 SLP (non-GMO soy lecithin phospholipid) absorption technology (Prodosome®). Objective: This randomized, double-blind placebo-controlled investigation assessed the safety and efficacy of N-SORB KD120 MEC in healthy male and female volunteers on various parameters of the blood, immunity, body composition, physical health, and quality of life following a 90-day intervention. Methods: Forty-six male and female (mean age: 25.8 ± 12.1 years) healthy volunteers were randomly assigned to receive either N-SORB (1 mL, twice daily) or placebo for 90 consecutive days. Complete blood count, as well as blood glucose, liver enzymes, and lipid profile were assessed pre- and post-intervention. Serum cytokine levels were determined by using a Bio-Plex Pro Human Cytokine 8-plex assay and enzyme linked immunosorbent assay (ELISA). Whole body composition analysis was performed by dual-energy x-ray absorptiometry (DEXA) to determine body fat mass, lean mass, and android and gynoid fat. Body weight, blood pressure, and physical health were assessed. Changes in quality of life were examined using the World Health Organization Quality of Life–abbreviated version and sleep quality was assessed using the 24-item Pittsburgh Sleep Quality Index (PSQI) questionnaire. Adverse events were monitored before, during, and after completion of the study. Results: Of the 46 subjects enrolled, a total of 40 subjects successfully completed the study. Compared to placebo, changes in blood cell counts including hematocrit, hemoglobin, mean corpuscular volume, platelets, and lymphocytes provide evidence of some improvement. Quality of life (QOL) parameters showed a small but significant improvement in the N-SORB group. A significant increase was observed in aspartate aminotransferase level in the placebo group at the end of 90 days of treatment; however, no increase was observed in the N-SORB group. No significant changes in blood urea nitrogen, serum creatinine, alkaline phosphatase, alanine aminotransferase, and lipid profile were observed between the placebo and treatment groups before and following intervention. No adverse effects were reported. Conclusions: This randomized, double blind, placebo-controlled clinical study demonstrates that short-term intervention with N-SORB improves the QOL and PSQI in healthy volunteers and did not significantly alter cardiometabolic parameters, lipid profile, or body composition.
- 11 March 2019
- Published by Taylor & Francis in Journal of the American College of Nutrition
- Vol. 38 (7) , 577-585
Safety and Efficacy of N-SORB®, a Proprietary KD120 MEC Metabolically Activated Enzyme Formulation: A Randomized, Double-Blind, Placebo-Controlled Study
Background: Enzymes are crucial for all aspects of metabolic function. Digestive enzymes from natural sources have been credited with beneficial effects in the digestion and absorption of food. N-SORB is a novel KD120 multienzyme complex (MEC) of metabolically activated enzymes composed of proteases, amylases, lipases, alpha-galactosidase, and glucoamylase from natural sources. These enzymes are encapsulated in a SK713 SLP (non-GMO soy lecithin phospholipid) absorption technology (Prodosome®). Objective: This randomized, double-blind placebo-controlled investigation assessed the safety and efficacy of N-SORB KD120 MEC in healthy male and female volunteers on various parameters of the blood, immunity, body composition, physical health, and quality of life following a 90-day intervention. Methods: Forty-six male and female (mean age: 25.8 ± 12.1 years) healthy volunteers were randomly assigned to receive either N-SORB (1 mL, twice daily) or placebo for 90 consecutive days. Complete blood count, as well as blood glucose, liver enzymes, and lipid profile were assessed pre- and post-intervention. Serum cytokine levels were determined by using a Bio-Plex Pro Human Cytokine 8-plex assay and enzyme linked immunosorbent assay (ELISA). Whole body composition analysis was performed by dual-energy x-ray absorptiometry (DEXA) to determine body fat mass, lean mass, and android and gynoid fat. Body weight, blood pressure, and physical health were assessed. Changes in quality of life were examined using the World Health Organization Quality of Life–abbreviated version and sleep quality was assessed using the 24-item Pittsburgh Sleep Quality Index (PSQI) questionnaire. Adverse events were monitored before, during, and after completion of the study. Results: Of the 46 subjects enrolled, a total of 40 subjects successfully completed the study. Compared to placebo, changes in blood cell counts including hematocrit, hemoglobin, mean corpuscular volume, platelets, and lymphocytes provide evidence of some improvement. Quality of life (QOL) parameters showed a small but significant improvement in the N-SORB group. A significant increase was observed in aspartate aminotransferase level in the placebo group at the end of 90 days of treatment; however, no increase was observed in the N-SORB group. No significant changes in blood urea nitrogen, serum creatinine, alkaline phosphatase, alanine aminotransferase, and lipid profile were observed between the placebo and treatment groups before and following intervention. No adverse effects were reported. Conclusions: This randomized, double blind, placebo-controlled clinical study demonstrates that short-term intervention with N-SORB improves the QOL and PSQI in healthy volunteers and did not significantly alter cardiometabolic parameters, lipid profile, or body composition.
- Open Access
- 5 October 2018
- Published by Wiley in The FASEB Journal
- Vol. 33 (2) , 2587-2598
Maternal obesity impairs fetal cardiomyocyte contractile function in sheep
Obesity is a major public health problem worldwide. In the United States, one‐third of women of reproductive age are obese. Human studies show that maternal obesity (MO) predisposes offspring to cardiovascular disease. However, the underlying mechanisms remain unclear. Given the similarities between pregnancy in sheep and humans, we studied sheep to examine the impact of MO on fetal cardiomyocyte contractility at term. We observed that MO impaired cardiomyocyte contractility by reducing peak shortening and shortening/relengthening velocity, prolonging time to relengthening. MO disrupted Ca 2+ homeostasis in fetal cardiomyocytes, increasing intracellular Ca 2+ and inducing cellular Ca 2+ insensitivity. The Ca 2+ ‐release channel was impaired, but Ca 2+ uptake was unaffected by MO. The upstream kinases that phosphorylate the Ca 2+ ‐release channel — ryanodine receptor‐2, PKA, and calmodulin‐dependent protein kinase II—were activated in MO fetuses. Contractile dysfunction was associated with an increased ratio of myosin heavy chain (MHC)‐β to MHC‐α and upregulated cardiac troponin (cTn)‐T and tropomyosin, as well as cTn‐I phosphorylation. In summary, this is the first characterization of the effects of MO on fetal cardiomyocyte contractility. Our findings indicate that MO impairs fetal cardiomyocyte contractility through altered intracellular Ca 2+ handling, overloading fetal cardiomyocyte intracellular Ca 2+ and aberrant myofilament protein composition. These mechanisms may contribute to developmental programming by MO of offspring cardiac function and predisposition to later life cardiovascular disease in the offspring.—Wang, Q., Zhu, C., Sun, M., Maimaiti, R., Ford, S. P., Nathanielsz, P. W., Ren, J., Guo, W. Maternal obesity impairs fetal cardiomyocyte contractile function in sheep. FASEB J. 33, 2587–2598 (2019). www.fasebj.org
- 5 October 2018
- Published by Wiley in The FASEB Journal
- Vol. 33 (2) , 2587-2598
Open AccessMaternal obesity impairs fetal cardiomyocyte contractile function in sheep
Obesity is a major public health problem worldwide. In the United States, one‐third of women of reproductive age are obese. Human studies show that maternal obesity (MO) predisposes offspring to cardiovascular disease. However, the underlying mechanisms remain unclear. Given the similarities between pregnancy in sheep and humans, we studied sheep to examine the impact of MO on fetal cardiomyocyte contractility at term. We observed that MO impaired cardiomyocyte contractility by reducing peak shortening and shortening/relengthening velocity, prolonging time to relengthening. MO disrupted Ca 2+ homeostasis in fetal cardiomyocytes, increasing intracellular Ca 2+ and inducing cellular Ca 2+ insensitivity. The Ca 2+ ‐release channel was impaired, but Ca 2+ uptake was unaffected by MO. The upstream kinases that phosphorylate the Ca 2+ ‐release channel — ryanodine receptor‐2, PKA, and calmodulin‐dependent protein kinase II—were activated in MO fetuses. Contractile dysfunction was associated with an increased ratio of myosin heavy chain (MHC)‐β to MHC‐α and upregulated cardiac troponin (cTn)‐T and tropomyosin, as well as cTn‐I phosphorylation. In summary, this is the first characterization of the effects of MO on fetal cardiomyocyte contractility. Our findings indicate that MO impairs fetal cardiomyocyte contractility through altered intracellular Ca 2+ handling, overloading fetal cardiomyocyte intracellular Ca 2+ and aberrant myofilament protein composition. These mechanisms may contribute to developmental programming by MO of offspring cardiac function and predisposition to later life cardiovascular disease in the offspring.—Wang, Q., Zhu, C., Sun, M., Maimaiti, R., Ford, S. P., Nathanielsz, P. W., Ren, J., Guo, W. Maternal obesity impairs fetal cardiomyocyte contractile function in sheep. FASEB J. 33, 2587–2598 (2019). www.fasebj.org
- Open Access
- 1 January 2018
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 14 (4) , 369-380
Splicing Factor RBM20 Regulates Transcriptional Network of Titin Associated and Calcium Handling Genes in The Heart
RNA binding motif 20 (RBM20) regulates pre-mRNA splicing of over thirty genes, among which titin is a major target. With RBM20 expression, titin expresses a larger isoform at fetal stage to a smaller isoform at adult resulting from alternative splicing, while, without RBM20, titin expresses exclusively a larger isoform throughout all ages. In addition to splicing regulation, it is unknown whether RBM20 also regulates gene expression. In this study, we employed Rbm20 knockout rats to investigate gene expression profile using Affymetrix expression array. We compared wild type to Rbm20 knockout at day1, 20 and 49. Bioinformatics analysis showed RBM20 regulates fewer genes expression at younger age and more at older age and commonly expressed genes have the same trends. GSEA indicated up-regulated genes are associated with heart failure. We examined titin binding partners. All titin direct binding partners are up-regulated and their increased expression is associated with dilated cardiomyopathy. Particularly, we found that genes involving calcium handling and muscle contraction are changed by RBM20. Intracellular calcium level measurement with individual cardiomyocytes further confirmed that changes of these proteins impact calcium handling. Selected genes from titin binding partners and calcium handling were validated with QPCR and western blotting. These data demonstrate that RBM20 regulates gene splicing as well as gene expression. Altered gene expression by RBM20 influences protein-protein interaction, calcium releasing and thus muscle contraction. Our results first reported gene expression impacted by RBM20 with heart maturation, and provided new insights into the role of RBM20 in the progression of heart failure.
- 1 January 2018
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 14 (4) , 369-380
Open AccessSplicing Factor RBM20 Regulates Transcriptional Network of Titin Associated and Calcium Handling Genes in The Heart
RNA binding motif 20 (RBM20) regulates pre-mRNA splicing of over thirty genes, among which titin is a major target. With RBM20 expression, titin expresses a larger isoform at fetal stage to a smaller isoform at adult resulting from alternative splicing, while, without RBM20, titin expresses exclusively a larger isoform throughout all ages. In addition to splicing regulation, it is unknown whether RBM20 also regulates gene expression. In this study, we employed Rbm20 knockout rats to investigate gene expression profile using Affymetrix expression array. We compared wild type to Rbm20 knockout at day1, 20 and 49. Bioinformatics analysis showed RBM20 regulates fewer genes expression at younger age and more at older age and commonly expressed genes have the same trends. GSEA indicated up-regulated genes are associated with heart failure. We examined titin binding partners. All titin direct binding partners are up-regulated and their increased expression is associated with dilated cardiomyopathy. Particularly, we found that genes involving calcium handling and muscle contraction are changed by RBM20. Intracellular calcium level measurement with individual cardiomyocytes further confirmed that changes of these proteins impact calcium handling. Selected genes from titin binding partners and calcium handling were validated with QPCR and western blotting. These data demonstrate that RBM20 regulates gene splicing as well as gene expression. Altered gene expression by RBM20 influences protein-protein interaction, calcium releasing and thus muscle contraction. Our results first reported gene expression impacted by RBM20 with heart maturation, and provided new insights into the role of RBM20 in the progression of heart failure.
- Open Access
- 18 September 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 568
Low carbon renewable natural gas production from coalbeds and implications for carbon capture and storage
Isotopic studies have shown that many of the world’s coalbed natural gas plays are secondary biogenic in origin, suggesting a potential for gas regeneration through enhanced microbial activities. The generation of biogas through biostimulation and bioaugmentation is limited to the bioavailability of coal-derived compounds and is considered carbon positive. Here we show that plant-derived carbohydrates can be used as alternative substrates for gas generation by the indigenous coal seam microorganisms. The results suggest that coalbeds can act as natural geobioreactors to produce low carbon renewable natural gas, which can be considered carbon neutral, or perhaps even carbon negative depending on the amount of carbon sequestered within the coal. In addition, coal bioavailability is no longer a limiting factor. This approach has the potential of bridging the gap between fossil fuels and renewable energy by utilizing existing coalbed natural gas infrastructure to produce low carbon renewable natural gas and reducing global warming.
- 18 September 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 568
Open AccessLow carbon renewable natural gas production from coalbeds and implications for carbon capture and storage
Isotopic studies have shown that many of the world’s coalbed natural gas plays are secondary biogenic in origin, suggesting a potential for gas regeneration through enhanced microbial activities. The generation of biogas through biostimulation and bioaugmentation is limited to the bioavailability of coal-derived compounds and is considered carbon positive. Here we show that plant-derived carbohydrates can be used as alternative substrates for gas generation by the indigenous coal seam microorganisms. The results suggest that coalbeds can act as natural geobioreactors to produce low carbon renewable natural gas, which can be considered carbon neutral, or perhaps even carbon negative depending on the amount of carbon sequestered within the coal. In addition, coal bioavailability is no longer a limiting factor. This approach has the potential of bridging the gap between fossil fuels and renewable energy by utilizing existing coalbed natural gas infrastructure to produce low carbon renewable natural gas and reducing global warming.
- 1 September 2016
- Published by Elsevier in Pharmacological Research
- Vol. 111, 357-373
mTOR-Independent autophagy inducer trehalose rescues against insulin resistance-induced myocardial contractile anomalies: Role of p38 MAPK and Foxo1
- 1 September 2016
- Published by Elsevier in Pharmacological Research
- Vol. 111, 357-373
mTOR-Independent autophagy inducer trehalose rescues against insulin resistance-induced myocardial contractile anomalies: Role of p38 MAPK and Foxo1